Nitroglycerin Injection

The main pharmacological action is to relax vascular smooth muscle. Nitroglycerin releases nitric oxide (NO), activates guanylate cyclase, increases cyclic guanosine monophosphate (cGMP) in smooth muscle and other tissues, leads to dephosphorylation of myosin light chain, regulates the contraction state of smooth muscle, and causes vasodilation. Nitroglycerin dilates the arteriovenous bed, mainly dilating the veins, and its effect intensity is dose-related. Peripheral vein dilation causes blood to remain in the periphery, reducing the amount of blood returning to the heart and reducing the left ventricular end-diastolic pressure (preload). Dilation of arteries reduces peripheral resistance (afterload). Arteriovenous dilation reduces myocardial oxygen consumption and relieves angina pectoris. It also has a dilating effect on epicardial coronary artery branches. Therapeutic doses can reduce systolic blood pressure, diastolic blood pressure and mean arterial pressure, and the effective coronary perfusion pressure can often be maintained, but when blood pressure is excessively reduced or heart rate increases, shortening the diastolic filling time, the effective coronary perfusion pressure is reduced. It reduces the increased central venous pressure and pulmonary capillary wedge pressure, pulmonary vascular resistance and systemic vascular resistance. Heart rate is usually slightly increased, presumably as a reflex of the drop in blood pressure. Cardiac index may increase, decrease, or remain unchanged. Patients with increased left ventricular filling pressure and peripheral resistance and low cardiac index may have an increased cardiac index. Conversely, patients with normal left ventricular filling pressure and cardiac index may have a slightly lower cardiac index with intravenous medication.

This product mainly contains nitroglycerin, molecular formula: C3H5N3O9, molecular weight: 227.09.

This product is a colorless clear liquid.

It is used for the treatment and prevention of angina pectoris caused by coronary heart disease, and can also be used to lower blood pressure or treat congestive heart failure.

Injection: Dilute with 5% glucose injection or sodium chloride injection and drip intravenously. The initial dose is 5 μg/min. It is best to use an infusion pump to infuse at a constant speed. For lowering blood pressure or treating heart failure, increase by 5 μg/min every 3 to 5 minutes. If it is ineffective at 20 μg/min, increase by 10 μg/min, and then 20 μg/min. Patients have individual differences in their response to this drug.

1Headache: may occur immediately after medication, may be severe and persistent. 2Dizziness, weakness, palpitations and other manifestations of postural hypotension may occur occasionally, especially in patients who are standing or immobilized. 3Therapeutic doses may cause significant hypotension reactions, manifested as nausea, vomiting, weakness, sweating, pallor and collapse. 4Syncope, flushing, drug rash and exfoliative dermatitis have all been reported.

It is contraindicated in patients with early myocardial infarction (with severe hypotension and tachycardia), severe anemia, glaucoma, increased intracranial pressure, and known allergy to nitroglycerin. It is also contraindicated in patients using sildenafil citrate (Viagra), which enhances the antihypertensive effect of nitroglycerin.

Precautions for children: The safety and efficacy of the drug for children are still uncertain. Precautions for pregnancy and lactation: It is not known whether it will cause fetal harm or affect fertility, so it should only be used in pregnant women when it is necessary. It is also not known whether it is excreted from human breast milk, so pregnant women should be cautious when using it intravenously. Precautions for the elderly: It is not yet clear. (To be supplemented)

1. Use of this drug may cause hypotension when drinking moderately or excessively. 2. Combination with antihypertensive drugs or vasodilators may enhance the postural hypotensive effect of nitrates. 3. Aspirin may reduce the clearance of sublingual nitroglycerin and enhance its hemodynamic effects. 4. The use of long-acting nitrates may reduce the therapeutic effect of sublingual medications. 5. Sildenafil citrate (Viagra) enhances the antihypertensive effect of organic nitrates. 6. The efficacy may be weakened when used in combination with acetylcholine, histamine and sympathomimetic amines.

Protect from light, seal tightly and store in a cool place.

1ml:5mg

24 months

Shanxi Kangbao Biological Product Co., Ltd.

• Founded in:

  1995-05-18

• Address:

  No. 151, Beihuan West Street, Luzhou District, Changzhi City, Shanxi Province

• Tax NO.:

  91140000602311789X

• Registered Funds:

  69.2 million yuan

• Email:

  Log in to view